Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide - The p53 breast cancer trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515135-29-00

Acronym

P53

Enrollment

Registered

2024-10-11

Start date

2024-10-12

Completion date

Unknown

Last updated

2024-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Brief summary

Objective response rate

Detailed description

pCR, Clinical benefit rate, Recurrence-free survival, safety and tolerability

Interventions

DRUGCyclophosphamid beta 1000 mg/2 ml Konzentrat zur Herstellung einer Injektions-/Infusionslösung

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
pCR, Clinical benefit rate, Recurrence-free survival, safety and tolerability	—

Primary

Measure	Time frame
Objective response rate	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026